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Interleukin-17A (IL-17A) contributes to the pathogenesis of arthritis. Data from experimental arthritis indicate IL-17 receptor sig-
naling as a critical pathway in turning an acute synovitis into a chronic destructive arthritis. The identification of six IL-17 family mem-
bers (IL-17A-F) may extend the role of this novel cytokine family in the pathogenesis of chronic destructive joint inflammation. Whether
the successful anti-IL-17A cytokine therapy in murine arthritis can be effectively translated to human arthritis need to be tested in clinical
trials in humans. Interestingly, IL-17A and IL-17F are secreted by the novel T helper subset named Th17. This novel pathogenic T cell
population induces autoimmune inflammation in mice and is far more efficient at inducing Th1-mediated autoimmune inflammation in
mice than classical Th1 cells (IFN-c). In addition to IL-17A and IL-17F, Th17 cells are characterized by expression of IL-6, TNF, GM-
CSF, IL-21, IL-22 and IL-26. Th17 cells have been established as a separate lineage of T helper cells in mice distinct from conventional
Th1 and Th2 cells. Whether this also applies to human Th17 and whether RA is a Th1 or a Th17 mediated disease is still not clear. This
review summarizes the findings about the role of IL-17 in arthritis and discusses the impact of the discovery of the novel Th17 cells for
arthritis. Further studies are needed to unravel the role of Th17 cells and the interplay of IL-17 and other Th17 cytokines in the path-
ogenesis of arthritis and whether regulating Th17 cell activity will have additional value compared to neutralizing IL-17A activity alone.
This might help to reach the ultimate goal not only to treat RA patients but to prevent the development of this crippling disease.
 2007 Elsevier Ltd. All rights reserved.
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Rheumatoid arthritis (RA) is a chronic systemic disor-
der characterized by autoimmunity, infiltration of joint
synovium by activated inflammatory cells, synovial hyper-
plasia, neoangiogenesis, and progressive destruction of car-
tilage and bone. This disease affects 1–2% of the population
worldwide, most commonly middle-aged women. The eti-
ology of RA is unknown but pro-inflammatory cytokines
play a central role in RA. Regulation of the cytokine dis-
balance might represent a solid way to control this disease.
The pro-inflammatory cytokines TNFa and IL-1 play a
crucial role in the pathogenesis of arthritis, driving1043-4666/$ - see front matter  2007 Elsevier Ltd. All rights reserved.
doi:10.1016/j.cyto.2007.09.014
* Corresponding author. Fax: +31 10 4635688.
E-mail address: e.lubberts@erasmusmc.nlenhanced production of cytokines, chemokines, and degra-
dative enzymes [1]. Clinical studies revealed efficacy after
blocking TNFa. However, a subset of patients does not
respond to anti-TNF and this treatment does not cure
the disease. Therefore, cytokines or factors other than IL-
1 and TNFa may also participate in the pro-inflammatory
cytokine cascade.
T cells represent a large proportion of the inflammatory
cells invading the synovial tissue. T cell activation and
migration into the synovium occurs as an early conse-
quence of disease, and these cells adopt a pro-inflammatory
phenotype. Considerable evidence now supports a role for
T cells in the initiation and perpetuation of the chronic
inflammation prevalent in RA. Interestingly, the vast
majority of these are (memory) T cells producing IL-17
that is up-regulated in early disease and is thought to con-
tribute to the inflammation associated with RA [2,3].
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Fig. 1. Schematic overview of the role of IL-17/Th17 in relation with other key cytokines and the cellular pathways of synovitis and concomitant joint
destruction. Is RA a Th1 or Th17 mediated disorder?
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mediators, such as IL-1 and TNFa from several joint cells
including synovial fibroblast, macrophages, and chondro-
cytes [4–7] (Fig. 1). In addition, IL-17A induces receptor
activator of NF-jB ligand (RANKL) expression that is
crucial for osteoclastogenesis and bone resorption
(Fig. 1). IL-17A can synergize with these cytokines (IL-1,
TNF, RANKL), but has direct activity as well. Further-
more IL-17A is able to promote cartilage destruction and
bone erosion in experimental arthritis [8,9]. When IL-17A
is combined with other cytokines, already thought to be
important in arthritic disease, even more marked tissue
destruction occurs (10, Lubberts unpublished observa-
tions). Moreover, IL-17 receptor signaling has been identi-
fied as a critical pathway in turning an acute synovitis into
a chronic destructive arthritis [11]. These observations
strongly implicate IL-17A as an important mediator of
arthritis.
2. Role of IL-17A in the pathogenesis of arthritis
2.1. Human studies
IL-17 is spontaneously produced by RA synovial mem-
brane cultures and IL-17-producing cells were found in the
T cell-rich area [2] and high levels have been detected in the
synovial fluid of patients with RA [2,12]. Although bioac-
tive IL-17 is detected in RA and osteoarthritis (OA) syno-
vial fluid, the levels of IL-17 were found to be higher in RAsynovial fluid when compared with osteoarthritis (OA)
synovial fluid [2,13]. Th1/Th0, but not Th2 subsets of
CD4+ T cell clones isolated from rheumatoid synovium
produced IL-17 [14]. IL-17 stimulates transcriptional NF-
jB activity and IL-6 and IL-8 secretion in fibroblastic,
endothelial, and epithelial cells, and induces T cell prolifer-
ation [5,6]. Furthermore, it triggers human synoviocytes to
produce GM-CSF, and PGE2 [6], suggesting that IL-17
could be an upstream mediator in the pathogenesis of
arthritis and may play a role in fine-tuning the inflamma-
tory response. Furthermore, T cell IL-17 stimulates the
production of IL-1 and TNFa from human macrophages
in vitro [7]. It enhances IL-1-mediated IL-6 production
by RA synoviocytes in vitro as well as TNFa-induced syn-
thesis of IL-1, IL-6 and IL-8 [15,16]. This indicates that IL-
17 synergize with IL-1 and TNF and it has been shown that
the combination of TNFa blockade with IL-1 and IL-17
blockade is more effective for controlling IL-6 production
in RA synovium cultures [10]. In addition, IL-17 induced
the expression of receptor activator of NF-jB ligand
(RANKL) in cultures of osteoblasts [13]. Furthermore,
in vitro studies showed the induction of metalloproteinases
by IL-17 in synoviocytes and chondrocytes [17–19]. Inter-
estingly, patients with early inflammatory arthritis who
subsequently developed RA had a distinct but transient
synovial fluid cytokine profile [3]. The levels of a range of
T cell, macrophage and stromal cell related cytokines
(e.g. IL-2, IL-4, IL-13, IL-17, IL-15, basic fibroblast
growth factor and epidermal growth factor) were
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after symptom onset [3]. In addition, this profile was no
longer present in established RA. In contrast, patients with
non-rheumatoid persistent synovitis exhibited elevated lev-
els of IFN-c at initiation [3]. In a 2-year prospective study,
multivariate analysis by several different methods consis-
tently demonstrated that synovial membrane mRNA levels
of IL-1b, TNFa, IL-10 and IL-17 were predictive of dam-
age progression [20]. IL-17 was synergistic with TNFa.
TNF and IL-17 effects were most pronounced with shorter
disease duration, and IL-1b effects were more pronounced
with longer disease duration. IFN-c was protective [20].
These data indicate that IL-17 is involved in early RA
development and joint destruction which is in line with
data from animal studies (Table 1). Furthermore, different
processes seem to be involved in early and late stage of RA
pathogenesis. Further insight in the critical cell type(s) and
cytokine interplay in the initial stage of RA development
may further improve RA therapy.
2.2. Experimental arthritis studies
In vivo animal studies revealed a critical role for IL-17
in the spontaneous development of destructive arthritis in
mice deficient in IL-1 receptor antagonist since crossing
IL-1ra deficient mice with IL-17 deficient mice results in
complete prevention of arthritis [21]. CIA was also mark-Table 1
Overview of the role of IL-17A in human and mouse studies of arthritis
Human studies
IL-17 expression Spontaneously produced by RA synovium/synovial fluid
IL-17 in
inflammation
IL-17 stimulates IL-6 and IL-8 in fibroblast, endothelial
epithelial cells [5,6]
IL-17 stimulates TNF, IL-1 in macrophages [7]
IL-17 stimulates GM-CSF, PGE2 in synoviocytes [6]
IL-17 in early
arthritis
Distinct but transient synovial fluid cytokine profile,
including IL-17 [3]
IL-17 and TNF most pronounced with shorter disease
duration [20]
IL-17 in
established
arthritis
Synovial expression of IL-17, IL-1, TNF, IL-10 [20]
IL-1 more pronounced with longer disease duration [20]
IFN-c protective [20]
IL-17 and
interplay with
TNF and IL-1
Enhances IL-1 mediated IL-6 in RA synoviocytes as we
as TNF-induced synthesis of IL-1, IL-6, IL-8 [15,16]
IL-17 synergize with IL-1, TNF [10,20,32]
IL-17 in bone
damage
IL-17 induces RANKL in cultures of osteoblasts [13]
Synergy between IL-17 and TNF [20,25,32]
IL-17 in cartilage
damage
IL-17 induces NO [34], metalloproteinases in synoviocyt
and chondrocytes [17–19]
Synergy between IL-17 and TNF [29]
Th17 IL-17-producing cells in the synovium of RA patients
(Th0/Th1 but not Th2) [14]edly although not completely suppressed in IL-17-deficient
mice [22] showing a lower collagen-specific T cell response
and collagen-specific IgG2a production. IL-17 receptor sig-
naling was essential in turning an acute synovitis into a
chronic destructive arthritis and a critical role for IL-17R
signaling in late-phase neutrophilia in the joint during pro-
gressive synovitis was shown [11]. Early neutralization of
endogenous IL-17 using the IL-17 receptor IgG1 Fc fusion
protein during the initial phase of arthritis suppresses the
onset of experimental arthritis [8,23]. Interestingly, a ther-
apeutic effect of anti-IL-17 cytokine therapy in collagen
arthritis was noted, implying that the T cell cytokine IL-
17 not only plays a role in the early stage of arthritis, but
also has a function in propagating and prolongation of
the arthritis [24].
In addition to joint inflammation, IL-17 has clear cata-
bolic effects on cartilage and bone [25–28,29,30]. Studies in
IL-17 receptor knockout mice revealed a critical role of IL-
17 receptor signaling in driving synovial expression of pro-
inflammatory and catabolic mediators, such as IL-1 and
different MMPs leading to less cartilage damage and bone
erosion in experimental arthritis [11,31]. Similar as for joint
inflammation, additive/synergistic catabolic effects were
noted between IL-17 and IL-1/TNF [29,32,33]. In vitro,
IL-17 suppresses matrix synthesis by articular chondro-
cytes through enhancement of nitric oxide (NO) produc-
tion [26,34–36]. However, it has been shown that theMouse studies
[2,12] Locally in synovium of arthritic mice [8,11]
and IL-17 induces synovial pro-inflammatory cytokines and
chemokines such as TNF, IL-1, IL-6, RANKL, KC, LIX [11,33]
Strong inducer of neutrophil recruitment through chemokine
release [8,9,33,78]
Lack of IL-17 activity prevents development of CIA [8,22–24]
and prevents spontaneous development of arthritis [21]
Blocking IL-17 prevents progression of late stage CIA [24] and
flare-up of experimental arthritis [11,31,33]
ll IL-17 additative/synergistic effect with TNF or IL-1 [33]
IL-17 effect is TNF dependent under naı¨ve conditions, but TNF
independent under arthritis conditions [38]
IL-17 effect is IL-1 independent in experimental arthritis [8,37]
IL-17 induces bone damage in naı¨ve mice, aggravates bone
erosion in CIA [44]
IL-17-induced bone erosion is RANKL mediated [44]
es Inducer of NO and MMPs and inhibition of PG synthesis [26],
aggravates cartilage erosion in CIA [8,9]
IL-1 independent role of IL-17 in cartilage damage [8,19,28]
IL-17-producing cells and Th17 in CIA and AIA arthritis
models [55,60,70]
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not dependent on IL-1 production by chondrocytes and
IL-1Ra did not block IL-17-induced matrix release nor pre-
vented inhibition of matrix synthesis in vitro using porcine
articular cartilage explants [28]. On the other hand, the IL-
17 induced production of prostaglandin E2 (PGE2) and
nitric oxide (NO) by cartilage explants is LIF-dependent
[28,36]. Interestingly, an IL-1-independent role of IL-17
in the pathogenesis of experimental arthritis was demon-
strated and IL-17 has the capacity to replace the catabolic
function of IL-1 in cartilage damage during experimental
arthritis [8,37]. Moreover, IL-17 acts independently of
TNF under arthritis conditions with no direct role for
IL-1 [38]. The downstream signaling pathways for IL-17
and IL-1 seem to be distinct and differential activation of
AP-1 members by IL-17 and IL-1b has been described
[39]. This underscores the potential of IL-17 to act addi-
tively or even synergistically with IL-1/TNF, but IL-17
may have direct catabolic effects as well.
Interestingly, the IL-17 family subtypes IL-17F and IL-
17E also showed cartilage destructive potential in vitro
[28,40]. Another IL-17 family member, IL-17B, has been
shown to be expressed by chondrocytes in normal bovine
articular cartilage, mostly in the mid and deep zones [41].
No functional studies with IL-17B have been reported.
Regulation of IL-17 and RANKL, as shown by IL-4
gene therapy in collagen arthritis, prevents osteoclasto-
genesis, bone erosion and cartilage destruction [42,43].
Early neutralization of IL-17 using sIL-17R:Fc fusion pro-
tein given systemically starting before arthritis expression
in experimental arthritis prevented bone erosion [8,23].
On the other hand, local IL-17 overexpression in the knee
joint of type II collagen-immunized mice results in promo-
tion of collagen arthritis and aggravates joint destruction
[9]. In the collagen-induced arthritis model it was shown
that IL-17 promoted bone erosion through loss of the
RANKL/OPG balance [44]. Systemic OPG treatment pre-
vented joint damage induced by local IL-17 gene transfer in
type II collagen-immunized mice. This strongly suggests
that IL-17 is a potent inducer of RANKL and that the
IL-17-induced promotion of bone erosion is strongly med-
iated by RANKL.
These studies strongly argue to target IL-17A in patients
with RA (Table 1). The first clinical trials of blocking IL-17
in patients with RA are ongoing. This will learn us whether
or not the successful anti-IL-17A cytokine therapy in mur-
ine arthritis can be effectively translated to human arthritis.
The timing at what stage in the arthritis process IL-17A
will be neutralized may be critical for the success of anti-
IL-17A therapy [3,20,33].
3. What is the most physiologically relevant target of IL-17A
in arthritis?
IL-17 mediates inflammation and tissue destruction
through a receptor (IL-17R) composed of two subunits,
IL-17RA and IL-17RC [45]. The IL-17R is a type I trans-membrane protein with no sequence similarity with any
other known cytokine receptor [5]. IL-17F was reported
to employ IL-17R for signaling and IL-17F and IL-17A
could induce IL-17R ubiquitination and DN-TRAF6, a
dominant-negative mutant, could block IL-17F but not
IL-17A triggered ubiquitination of IL-17R [46]. The IL-
17R is ubiquitously expressed in virtually all cells and tis-
sue and its expression was shown on synoviocytes, chon-
drocytes and synovial endothelial cells [47–49].
Expression of different IL-17 homologs (IL-17A, C, E
and F) was detected in synovial fluid mononuclear cells
from RA patients and different IL-17R (IL-17RA, IL-
17RB, C and D) expression was noted in fibroblast-like
synoviocytes of RA patients [50]. Effects of IL-17 on many
cells have been reported including fibroblast, monocytes,
osteoblast, endothelial cells and chondrocytes [6,7,32,33].
Since the IL-17R is expressed on many cell types the ques-
tion arise what is the (most) relevant target for IL-17 sig-
naling in inducing chronic inflammatory joint disease.
Bone marrow chimeric mice revealed the need for IL-17R
expression on radiation-resistant joint cells for destructive
joint inflammation [11]. Chimeric mice of host wt and
donor IL-17R-/- bone marrow (BM) cells developed
destructive synovitis after repeated injection of bacterial
cell wall fragments in the joint similar to wtfi wt chimeras.
In contrast, chimeric mice of host IL-17R/ and donor
wt BM cells were protected from chronic destructive arthri-
tis similar as IL-17R/fi IL-17R/ chimeras. In these
chimeras a high degree of chimerism in myeloid cells with
>90% engraftment in peripheral blood was achieved. No
difference in IL-17-positive cells in these four groups of
BM chimeric mice was noted suggesting that IL-17R sig-
naling between dendritic cells and T cells is not necessary
for IL-17 production. To speculate about the origin of
these radiation-resistant cell types, fibroblast-like synovio-
cytes, synovial macrophages as well as endothelial cells
are potential candidates. During arthritis, IL-17R positive
cells are fibroblast-like cells, chondrocytes, mononuclear
cells, endothelial cells, bone lining cells, and many poly-
morphonuclear cells [11]. Further studies in cell-type spe-
cific IL-17R knockout/knockin mice are needed to fully
identify the most relevant IL-17 responding cell type(s) that
are critical in the IL-17-induced chronic inflammatory
arthritis process.
4. Th17 cells/Th17 cytokines in arthritis
Recently a novel pathogenic T cell population (Th17
cells) has been identified which induces autoimmune
inflammation in mice [51]. These cells are far more efficient
at inducing Th1-mediated autoimmune inflammation in
mice than classical Th1 cells (IFN-c). First it was shown
that Th17 cells were induced by a novel member of the
IL-12 (p35/p40) family, IL-23 (p19/p40). Dendritic cells
(DC) secrete cytokines of the IL-12 family such as IL-12
and IL-27 (p28/p40) and play a role in Th1 cell prolifera-
tion and activation leading to the production of IFN-c.
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cells through a mechanism distinct from the signals driving
the development of Th1 cells and Th2 cells. Neutralization
of both IFN-c and IL-4 has been found to favor IL-23-
induced IL-17-producing cells [52,53]. In addition, IL-23
is required for in vivo development of Th17 cell-mediated
diseases such as EAE and CIA [51,54,55]. However, later
it became clear that IL-23 can not drive de novo Th17 cell
differentiation from naı¨ve CD4+ T cells in vitro [56].
Instead, de novo Th17 cell differentiation is driven by the
combination of IL-6 and transforming growth factor-b1
(TGF-b1) [56–58]. During development induced by IL-6
and TGF-b, Th17 cells become responsive to IL-23 and
IL-23 subsequently serves as a survival factor for commit-
ted Th17 cells [56]. However, it matters whether IL-23 is
present in addition to TGF-b and IL-6 regarding the cyto-
kine profile expressed by Th17 cells [59,60]. Recently, a new
player is added to this concept through the finding that
Th17 cells produce IL-21, which creates an amplification
loop for further generation of Th17 cells [61,62]. Th17 cells
are characterized by the expression of IL-17 (IL-17A) and
also reportedly express IL-17F, IL-6, tumor necrosis factor
(TNF), granulocyte-macrophage colony-stimulating factor
(GM-CSF), IL-21, IL-22 and in humans also IL-26 but nei-
ther interferon-c (IFN-c) nor IL-4 [51–53,59,61–66]. In
mice, Th17 cells have been established as a separate lineage
of T helper cells distinct from conventional Th1 and Th2
cells [52,53]. Transcription factors and signaling molecules
that are important for the differentiation of Th1 or Th2
cells, including STAT1,4,6 (signal transducers and activa-
tors of transcription) and T-bet, are dispensable for the
development of Th17 cells [52,53]. Recently, RORct was
discovered as a novel Th17 transcription factor [67]. More-
over, Th1 cytokines (IFN-c, IL-12, IL-27) and Th2 cyto-
kines (IL-4, IL13) repress Th17 cell development
[52,53,68,69]. T cell specific overexpression of GATA3, a
Th2 specific transcription factor, prevented Th17 polariza-
tion accompanied with suppression of chronic joint inflam-
mation and bone destruction [70].
Human Th17 (hTh17) cells are identified as bearing a
CCR2+CCR5 phenotype [71]. Furthermore, expression
of CCR6 and CCR4 together identified human memory
CD4+ T cells selectively producing IL-17 and expressing
mRNA encoding the human ortholog of mouse RORct,
whereas CCR6 and CXCR3 identified Th1 cells producing
IFN-c and T helper cells producing both IFN-c and IL-17
[72]. Therefore, selective markers for human Th17 cells
may help us to understand the pathogenic role of this
intriguing new T cell subset. Interestingly, the identification
of a subset of cells sharing features of both human Th1 and
human Th17, which can arise from the modulation
of hTh17 cells by IL-12, raises new issues concerning
development and/or functional relationship between Th17
and Th1 [73].
Since IL-17A is a T cell factor produced by the novel
Th17 subset, the question rises whether RA is a Th1 or a
Th17 associated disorder (Fig. 1). On the other hand, adevelopmental and/or functional relationship between
Th17 and Th1 [73] may be relevant for RA since IL-17 is
produced by some pro-inflammatory Th1/Th0 cells iso-
lated from synovial membranes and synovial fluid of RA
patients [14,74] and IL-17 co-expresses with TNF and
GM-CSF in patients with Lyme arthritis [63]. Further stud-
ies are needed to clarify the hTh1/hTh17 relationship in
chronic arthritis. In line with these human studies, single
IL-17 and IFN-c as well as double IL-17/IFN-c positive
cells were noted in mice immunized with type II collagen
(55, Lubberts et al. unpublished observations). Further-
more, the highly self-reactive T cells produced in mice as
a result of genetically altered thymic T cell selection spon-
taneously differentiate into IL-17-secreting CD4+ T helper
cells, which mediate an autoimmune arthritis that clinically
and immunologically resembles RA [75]. Deficiency of
either IL-17 or IL-6 completely inhibited arthritis develop-
ment, whereas IFN-c deficiency exacerbated arthritis.
However, the generation, differentiation, and persistence
of arthritogenic Th17 cells per se were insufficient for pro-
ducing overt autoimmune arthritis [75]. In line with the
important role of IL-17 in bone erosion via RANKL,
Th17 cells express membrane bound RANKL and play
an important role in the bone destruction phase of autoim-
mune arthritis [76].
Th17 cells may play a critical role in chronic destructive
arthritis as well as other chronic inflammatory diseases.
Specific depletion of this autoimmune driven T cell subset
may be more effective as a therapy than blocking IL-12,
IL-23 or IL-17 alone. In addition, it is expected that spe-
cific depletion of Th17 cells will keep the IL-12/Th1
immune pathway intact, which is an effective pathway for
targeting many intracellular microbial infections and is
important for the IFN-c production that is required to
resolve these infections. On the other hand, the role of
the IL-23/IL-17 axis is less clear but it seems to be limited
in immunity to intracellular pathogens and is more evident
in the absence of IL-12 [77,78].
5. Conclusion
RA is a chronic disorder with unknown etiology, char-
acterized by autoimmunity and progressive destruction of
cartilage and bone. In vitro and data from experimental
arthritis models indicate IL-17 as an important player in
the pathogenesis of arthritis. The identification of six IL-
17 family members (IL-17A–F) may extend the role of this
novel cytokine family in the pathogenesis of chronic
destructive joint inflammation [79]. IL-17A is a potent
inducer of RANKL and demonstrates additive or even syn-
ergistic effects with IL-1 and TNF in inducing joint pathol-
ogy. However, IL-17A has the capacity to induce chronic
destructive arthritis in an IL-1 and TNF independent
way. Whether the successful anti-IL-17A cytokine therapy
in murine arthritis can be effectively translated to human
arthritis need to be tested in clinical trials in humans. Inter-
estingly, IL-17A and IL-17F are secreted by the novel T
E. Lubberts / Cytokine 41 (2008) 84–91 89helper subset named Th17 cells. This novel pathogenic T
cell population induces autoimmune inflammation in mice.
Th17 cells are far more efficient at inducing Th1-mediated
autoimmune inflammation in mice than classical Th1 cells
(IFN-c). Whether this also accounts for human Th17 and
whether RA is a Th1 or a Th17 mediated disease is still
not clear.
The majority of patient’s newly presenting arthritis have
a self-limiting disease (60%), while 40% proceed to a
chronic arthritis from which 62% will develop chronic
destructive arthritis (RA) [80]. Different processes and
cytokine interactions seem to be involved in early and late
stage of RA pathogenesis. IL-17 has been shown to be
involved in the early RA development and joint destruc-
tion. From experimental arthritis studies we know that
IL-17 receptor signaling is critical in turning an acute syno-
vitis into a chronic destructive arthritis. Therefore, it is
tempting to speculate that regulating/targeting the IL-17/
Th17 immune pathway may improve RA therapy. Further
studies are needed to unravel the role of Th17 and the
interplay of IL-17A and other Th17 cytokines in the path-
ogenesis of arthritis and whether regulating/targeting Th17
cells will have additional value compared to neutralizing
IL-17A activity alone. This might lead to the road to reach
the ultimate goal and that is to prevent the development of
this crippling disease.References
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